Skip to content
10-Q

Quarterly Report

AOXING PHARMACEUTICAL COMPANY, INC.

0001096906-16-001598

← back to feed
Filed
May 16, 2016 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2016 · May 16, 2016 76.21M sh
Short Term Debt Q3 2016 · Mar 31, 2016 $11.51M
Short Term Debt Q3 2016 · Jun 30, 2015 $12.48M
Stockholders Equity Q3 2016 · Mar 31, 2016 $21.52M
Stockholders Equity Q3 2016 · Jun 30, 2015 $11.24M
Current Liabilities Q3 2016 · Mar 31, 2016 $38.03M
Current Liabilities Q3 2016 · Jun 30, 2015 $41.24M
Current Assets Q3 2016 · Mar 31, 2016 $29.32M
Current Assets Q3 2016 · Jun 30, 2015 $21.1M
Total Assets Q3 2016 · Mar 31, 2016 $58.93M
Total Assets Q3 2016 · Jun 30, 2015 $53.04M
Shares Diluted Q3 2016 · Mar 31, 2015 67.68M sh
Shares Diluted Q3 2016 · Mar 31, 2015 60.95M sh
Capex Q3 2016 · Mar 31, 2015 $3.01M
Operating Cash Flow Q3 2016 · Mar 31, 2015 $5.15M
Eps Diluted Q3 2016 · Mar 31, 2015 $0.01
Eps Diluted Q3 2016 · Mar 31, 2015 $0.02
Eps Basic Q3 2016 · Mar 31, 2015 $0.01
Eps Basic Q3 2016 · Mar 31, 2015 $0.02
Sga Expense Q3 2016 · Mar 31, 2015 $662.07K
Sga Expense Q3 2016 · Mar 31, 2015 $1.99M
Rd Expense Q3 2016 · Mar 31, 2015 $73.97K
Rd Expense Q3 2016 · Mar 31, 2015 $277.12K
Net Income restated Q3 2016 · Mar 31, 2015 $777.98K
Net Income restated Q3 2016 · Mar 31, 2015 $1.34M
Operating Income Q3 2016 · Mar 31, 2015 $2.09M
Operating Income Q3 2016 · Mar 31, 2015 $5.28M
Gross Profit Q3 2016 · Mar 31, 2015 $5.51M
Gross Profit Q3 2016 · Mar 31, 2015 $13.5M
Cost Of Revenue Q3 2016 · Mar 31, 2015 $1.08M
Cost Of Revenue Q3 2016 · Mar 31, 2015 $4.09M